McGill University and Genome Quebec Innovation Center
Ontology highlight
ABSTRACT:
PROVIDER: EGAO00000000333 | EGA |
REPOSITORIES: EGA
Similar Datasets
Project description:BioID datasets of wt, Q and S in the absence and presence of oleate. Tetracyclin-induced Rab18-BirA* hybrid proteins stably expressed in HEK293 cells. Included also, NBirA* plus minus oleate induced and expressed as controls.
2024-01-26 | PXD016631 | Pride
Project description:BackgroundPercutaneous kidney biopsies are essential for diagnosis and management of kidney diseases. However, post-procedural bleeding is a significant risk associated with biopsies. At the McGill University Health Center, the 2 main hospitals, the Royal Victoria Hospital and the Montreal General Hospital, have different observation protocols for outpatient native kidney biopsies. Currently, patients are admitted for a 24-hour inpatient observation at the Montreal General Hospital, whereas patients biopsied at the Royal Victoria Hospital are discharged after 6 to 8 hours of observation at the end of the day. Most Canadian centers do not admit patients for an overnight observation, and it was unclear why this practice continued at the Montreal General Hospital.ObjectiveOur objective was to determine the incidence of complications post-renal biopsy over the past 5 years at both hospital sites, and compare them to each other, as well as to established rates in the available literature.DesignThis assessment was designed as a quality assurance audit.SettingThis audit was conducted from a local registry of renal biopsies performed at the McGill University Health Center between January 2015 to January 2020.PatientsWe included all adult patients (between the ages 18 and 80) with outpatient native kidney biopsies performed at the McGill University Health Center between 2015 and 2020.MeasurementsWe collected the included patients' baseline demographics and risk factors at the time of biopsy, including age, BMI, creatinine, estimated glomerular filtration rate, pre- and post-biopsy hemoglobin, platelet, urea, coagulation profile, blood pressure, kidney side/size as well as needle size, and number of passes made.MethodsWe compared the incidence of both minor and major bleeding complications at the Montreal General and the Royal Victoria Hospital. Variables that were measured included hemoglobin before and after biopsy, incidence of minor bleeding complications (defined by hematomas and gross hematuria), and incidence of major complications (defined by post-biopsy bleeding requiring either transfusions or another procedure to stop the bleeding), as well as the incidence of admissions post-biopsy.ResultsThe incidence of major complications was 2.87% over 5 years (5/174 patients), which is comparable with that reported in the literature. Our transfusion incidence was 1.72% (3/174 patients) and our embolization incidence was 2.3% (4/174 patients) over the 5 study years. Our total number of major events was low and the patients who had major events had significant risk factors for bleeding. All events occurred within 6 hours of observation.LimitationsThis was a retrospective study with a low event number. Additionally, since the events included only those recorded at the McGill University Health Center, it is possible that the events of interest may have occurred at other hospital sites without the author's knowledge.ConclusionsBased on the results of this audit, all major bleeding events occurred within 6 hours of a percutaneous kidney biopsy, suggesting that patients should be monitored for 6 to 8 hours following biopsy. The next step after this quality assurance audit is a quality improvement project and a cost-effectiveness analysis to assess whether post-biopsy practices should be amended at the McGill University Health Center.
| S-EPMC10259123 | biostudies-literature
Project description:Organisation EGAO00000000177
| EGAO00000000177 | EGA
Project description:Organisation EGAO00000001206
| EGAO00000001206 | EGA
Project description:Organisation EGAO00000001053
| EGAO00000001053 | EGA
Project description:Organisation EGAO00000001038
| EGAO00000001038 | EGA
Project description:Organisation EGAO00000000816
| EGAO00000000816 | EGA
Project description:Organisation EGAO00000000688
| EGAO00000000688 | EGA